Patrick Burgermeister joins Kizoo Technology Capital
Kizoo Technology Capital today announced that they strengthened their team with the addition of Patrick Burgermeister. He joins Kizoo coming from the Venture Capital group BioMedPartners (Basel, Switzerland) where he was one of the partners and supported various biotech companies as a director on their boards. Patrick has a strong operational background in venture capital, pharma, banking and medtech.
Before BioMedPartners, he was Senior Portfolio Manager of project management at Novartis Pharma. There, he was responsible for the evaluation and prioritisation of development projects from preclinical to registration stage. Priorto Novartis, he was Senior Financial Analyst responsible for the European Biotech and Pharma sector at Zürcher Kantonalbank. In addition, he served as advisor to the healthcare fund Pharma Vision. Before that, he worked as strategic planning manager at Jomed AG (now Abbott Vascular).
Patrick was also a successful business developer for early-stage biotech companies and led collaboration and licensing deals with public and private companies. Among others, he headed the business development at Apeiron Biologics (Vienna, Austria) and at BioVersys AG (Basel, Switzerland). He also served as chairman of a dermatology startup and is board member of the business angel club BioBAC.
Patrick holds a Master’s degree in Molecular Biology from the University of Basel (Biozentrum), a Master’s degree in Business Administration from the University of St. Gallen (HSG) and a degree as Chartered Financial Analyst (CFA).